MISSISSAUGA, ON, Might 4, 2021 /CNW/ – ZEJULA (niraparib) has acquired conditional constructive suggestions for reimbursement from the Canadian Company of Medicine and Know-how in Well being (CADTH) and L’Institut nationwide d’excellence en santé et en providers sociaux (INESSS), each Canadian Well being Know-how Evaluation (HTA) our bodies.
The organizations advocate reimbursement for ZEJULA for monotherapy upkeep remedy of feminine grownup sufferers with newly recognized epithelial ovarian, fallopian tube, or major peritoneal most cancers who’re in an entire or partial response to platinum-based chemotherapy. ZEJULA acquired Discover of Compliance (NOC) from Well being Canada for first-line monotherapy upkeep remedy for girls with platinum-responsive superior ovarian most cancers in October, 2020.
“These suggestions are a constructive and important step ahead in making certain that each one ladies who may doubtlessly profit from ZEJULA are ready to take action,” stated Alex Romanovschi, MD, Nation Medical Director at GSK. “We proceed to work in direction of broad reimbursement in collaboration with Canadian public payers. Within the interim, ZEJULA stays accessible for applicable sufferers through the GSK Affected person Assist Program.”
Ovarian most cancers is most ceaselessly recognized in ladies aged 55 to 64 years (median age 63 years), is the fifth commonest most cancers for girls and is probably the most severe ladies’s most cancers.1,2
“Yearly ovarian most cancers claims 1,950 lives, and it is estimated 3,100 Canadian ladies can be newly recognized with this illness this 12 months” stated Elisabeth Baugh, CEO of Ovarian Most cancers Canada. ” However the arrival of recent medicine resembling Zejula is beginning to change outcomes of the illness and can assist guarantee ladies with ovarian most cancers can thrive.”
Full particulars on the suggestions, together with really helpful standards for reimbursement, can be found on the CADTH website (https://cadth.ca/niraparib-zejula-first-line-ovarian-cancer-details) and INESSS website (https://www.inesss.qc.ca/en/themes/medicaments/drug-products-undergoing-evaluation-and-evaluated/extract-notice-to-the-minister/zejula-projet-aligne-inesss-acmts-sante-canada-5624.html?DemandePluginController%5Bonglet%5D=0&cHash=00ffdd9fa17d8655f8ba588589587dc1).
GSK can be working in collaboration with the pan-Canadian Pharmaceutical Alliance (pCPA) and private and non-private payers to make sure that they’ve the information and knowledge required to make well timed reimbursement choices for ZEJULA. GSK is dedicated to making sure that sufferers can entry ZEJULA by public funding as quickly as potential.
About ZEJULA (niraparib)
ZEJULA is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor. The approval of ZEJULA within the first-line setting was based mostly on the outcomes of the section III PRIMA research (ENGOT-OV26/GOG-3012)3, which enrolled sufferers with newly recognized superior ovarian most cancers following an entire or partial response to platinum-based chemotherapy no matter biomarker standing.
GSK is a science-led world healthcare firm with a particular goal: to assist individuals do extra, really feel higher, dwell longer. For additional data, please go to www.ca.gsk.com
Past ZEJULA, GSK has an intensive and various oncology pipeline, enriched by the 2019 acquisition of TESARO and the worldwide alliance with MERCK KGaA, offering entry to new scientific capabilities and experience that can improve the tempo and scale at which we might help sufferers dwelling with most cancers.
SOURCE GlaxoSmithKline Inc.
For additional data: Company Communications, +1 905-819-3363 (Mississauga), +1 450-680-4812 (Laval)